Jordo Bivona

Editor's Choice

  • A Prime Example Of Success In Strategy Implementation

    By Jordo Bivona - February 5, 2013 | Tickers: CHK, CLR, EOG | Editor's Choice

    Despite the long trough in natural gas prices, the stock of EOG Resources (NYSE: EOG) is near record highs. Below, I will explain how EOG's continued success in strategy implementation has led it to this point, and how this will enable the company to keep up its high rate of growth.

    What Happened?

    This strong performance has been driven by the successful implementation of the strategy to generate organic more »

  • How Will Annaly React To Fiscal Cliff Agreement?

    By Jordo Bivona - January 7, 2013 | Tickers: NLY, ARR, CMO, HTS | Editor's Choice

    Americans are mixed on the "fiscal cliff" agreement reached by Congress and signed into law by President Barack Obama. 43% of Americans approve of the decision that was agreed upon, while 45% disapprove of the decision. The fiscal cliff agreement will dissolve some, but not all, of the negative economic impacts of going over the cliff. Most importantly, the agreement will extend the Bush-era tax cuts for the vast majority more »

  • Go Long on This Big Pharma

    By Jordo Bivona - December 18, 2012 | Tickers: LLY, GSK, MRK, PFE | Editor's Choice

    While Merck's (NYSE: MRK) Singulair will still retain exclusivity in Japan until 2016, other new products could help to replace lost revenue from Singulair, including the insomnia drug Suvorexant, the neuromuscular reversal agent Bridion, the drug titled V503 that is used in the prevention of HPV associated cancers, the cholesterol drug Tredaptive, and Vintafolide, a late stage oncology drug. I will discuss each specifically to see what they could more »